1169846-35-8 Usage
Description
(2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)pyrrolidine-2-carboxamide hydrochloride is a complex organic compound featuring a pyrrolidine core with various functional groups. It is characterized by the presence of a chloro and methoxy substituent on an isoquinolin-1-yl group, as well as a cyclopropylsulfonylcarbamoyl and vinylcyclopropyl moiety. The hydrochloride salt form suggests that the compound carries a positive charge balanced by a chloride counterion. This intricate molecular architecture positions it as a candidate of interest for pharmaceutical research and development, with potential biological activities stemming from its sophisticated structure.
Uses
Used in Pharmaceutical Research and Development:
(2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)pyrrolidine-2-carboxamide hydrochloride is utilized as a compound of interest in pharmaceutical research and development due to its unique structural features. The presence of various functional groups and the potential for specific biological activity make it a promising candidate for the development of new drugs targeting a range of therapeutic areas.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, this compound serves as a valuable starting point for the design and synthesis of novel therapeutic agents. Its complex structure allows for systematic modifications to explore structure-activity relationships and optimize pharmacological properties such as potency, selectivity, and pharmacokinetics.
Used in Drug Discovery:
(2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)pyrrolidine-2-carboxamide hydrochloride is employed in drug discovery processes to identify new lead compounds or to improve existing drug candidates. Its unique structural elements can be leveraged to target specific biological pathways or receptors, potentially leading to the development of innovative treatments for various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 1169846-35-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,9,8,4 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1169846-35:
(9*1)+(8*1)+(7*6)+(6*9)+(5*8)+(4*4)+(3*6)+(2*3)+(1*5)=198
198 % 10 = 8
So 1169846-35-8 is a valid CAS Registry Number.
1169846-35-8Relevant articles and documents
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection
Scola, Paul M.,Sun, Li-Qiang,Wang, Alan Xiangdong,Chen, Jie,Sin, Ny,Venables, Brian L.,Sit, Sing-Yuen,Chen, Yan,Cocuzza, Anthony,Bilder, Donna M.,D'Andrea, Stanley V.,Zheng, Barbara,Hewawasam, Piyasena,Tu, Yong,Friborg, Jacques,Falk, Paul,Hernandez, Dennis,Levine, Steven,Chen, Chaoqun,Yu, Fei,Sheaffer, Amy K.,Zhai, Guangzhi,Barry, Diana,Knipe, Jay O.,Han, Yong-Hae,Schartman, Richard,Donoso, Maria,Mosure, Kathy,Sinz, Michael W.,Zvyaga, Tatyana,Good, Andrew C.,Rajamani, Ramkumar,Kish, Kevin,Tredup, Jeffrey,Klei, Herbert E.,Gao, Qi,Mueller, Luciano,Colonno, Richard J.,Grasela, Dennis M.,Adams, Stephen P.,Loy, James,Levesque, Paul C.,Sun, Huabin,Shi, Hong,Sun, Lucy,Warner, William,Li, Danshi,Zhu, Jialong,Meanwell, Nicholas A.,McPhee, Fiona
, p. 1730 - 1752 (2014/04/03)
The discovery of asunaprevir (BMS-650032, 24) is described. This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clinical trials for the treatment of hepatitis C virus infection. The discovery of 24 was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chemical series, BMS-605339 (1), from clinical trials. The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the molecule had a significant impact on the CV profile of a given compound. The antiviral activity, preclincial PK profile, and toxicology studies in rat and dog supported clinical development of BMS-650032 (24).
